Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Next Previous
X
Search
Trial Profile

An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Expanded access
  • Acronyms ACCESS
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society.
    • 05 Nov 2015 Status changed from completed to recruiting, as reported by ClinicalTrials.gov record
    • 05 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top